Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review (JACC June 2024-1)-Article: Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review

Article: Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review

Pdf Summary

Arrhythmia-induced cardiomyopathy (AiCM) is a reversible form of dilated cardiomyopathy caused by arrhythmias like tachycardia, atrial fibrillation, and premature ventricular contractions. Diagnosis involves confirming cardiomyopathy reversal upon eliminating the responsible arrhythmia, with treatment focusing on managing the specific arrhythmia and associated comorbidities. Left ventricular function restoration can improve outcomes and quality of life. Tachycardia-induced cardiomyopathy (T-CM) and premature ventricular contraction cardiomyopathy (PVC-CM) are subtypes of AiCM, with studies indicating predictors for PVC-CM and the effectiveness of ablation therapy in reducing PVC burden and improving outcomes. Managing PVCs in individuals without left ventricular dysfunction, predicting outcomes like adverse effects of left bundle branch block, and comparing treatment strategies such as ablation and drug therapy remain areas of interest. Early diagnosis and treatment are crucial in preventing CM-related hospitalizations and device implantations. More research is needed to develop effective long-term strategies for PVC suppression and CM prevention. Patient monitoring and proper management play a key role in improving outcomes for individuals with PVC-related CM.

Keywords

Arrhythmia-induced cardiomyopathy

AiCM

Reversible dilated cardiomyopathy

Tachycardia

Atrial fibrillation

Premature ventricular contractions

Left ventricular function restoration

Tachycardia-induced cardiomyopathy

PVC-CM

Ablation therapy